Alaunos Therapeutics Inc (FRA:WEK)

€ 1.41 0 (0%) Market Cap: 326.90 Mil Enterprise Value: 325.29 Mil PE Ratio: 0 PB Ratio: 1.08 GF Score: 60/100

Q1 2023 Alaunos Therapeutics Inc Earnings Call Transcript
May 10, 2023

Earnings
Alaunos Therapeutics Inc at Needham Healthcare Conference (Virtual) Transcript
Apr 17, 2023
Q4 2022 Alaunos Therapeutics Inc Earnings Call Transcript
Mar 07, 2023

Earnings
Q3 2022 Alaunos Therapeutics Inc Earnings Call Transcript
Nov 14, 2022

Earnings
Q2 2022 Alaunos Therapeutics Inc Earnings Call Transcript
Aug 15, 2022

Earnings
Q1 2022 Alaunos Therapeutics Inc Earnings Call Transcript
May 16, 2022

Earnings
Q4 2021 Alaunos Therapeutics Inc Earnings Call Transcript
Mar 30, 2022

Earnings
Q3 2021 ZIOPHARM Oncology Inc Earnings Call Transcript
Nov 08, 2021

Earnings
ZIOPHARM Oncology Inc Corporate Update Conference Call Transcript
Aug 30, 2021
Q2 2021 ZIOPHARM Oncology Inc Earnings Call Transcript
Aug 09, 2021

€1.93 (+0.52%)

Earnings
ZIOPHARM Oncology Inc at Raymond James Human Health Innovation Conference (Virtual) Transcript
Jun 22, 2021
ZIOPHARM Oncology Inc Annual Shareholders Meeting Transcript
May 19, 2021
Q1 2021 ZIOPHARM Oncology Inc Earnings Call Transcript
May 06, 2021

€2.48 (-2.36%)

Earnings
ZIOPHARM Oncology, Inc. - Special Call Transcript
Mar 11, 2021
Q4 2020 ZIOPHARM Oncology Inc Earnings Call Transcript
Feb 25, 2021

€3.86 (-3.02%)

Earnings
ZIOPHARM Oncology Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 14, 2021
Q3 2020 ZIOPHARM Oncology Inc Earnings Call Transcript
Nov 05, 2020

€2.08 (+9.47%)

Earnings
Q2 2020 ZIOPHARM Oncology Inc Earnings Call Transcript
Aug 06, 2020

€2.72 (+2.26%)

Earnings
ZIOPHARM Oncology Inc Annual Shareholders Meeting Transcript
Jun 29, 2020
ZIOPHARM Oncology Inc at Bank of America Merrill Lynch Healthcare Conference (Virtual) Transcript
May 14, 2020
Q1 2020 ZIOPHARM Oncology Inc Earnings Call Transcript
May 07, 2020

€2.38 (-3.25%)

Earnings
Q4 2019 ZIOPHARM Oncology Inc Earnings Call Transcript
Mar 02, 2020

€2.68 (+1.52%)

Earnings
ZIOPHARM Oncology Inc at JPMorgan Healthcare Conference Transcript
Jan 16, 2020
Q3 2019 ZIOPHARM Oncology Inc Earnings Call Transcript
Nov 07, 2019

€3.72 (-4.12%)

Earnings
ZIOPHARM Oncology Inc at Morgan Stanley Healthcare Conference Transcript
Sep 09, 2019
Q2 2019 ZIOPHARM Oncology Inc Earnings Call Transcript
Aug 08, 2019

€5.46 (+1.30%)

Earnings
ZIOPHARM Oncology Inc to Discuss TCR-T Program Conference Call Transcript
Jun 12, 2019
Q1 2019 ZIOPHARM Oncology Inc Earnings Call Transcript
May 08, 2019

€3.82 (-8.61%)

Earnings
Q4 2018 ZIOPHARM Oncology Inc Earnings Call Transcript
Mar 05, 2019

€2.52 (-0.40%)

Earnings

ZIOPHARM Oncology Inc at JPMorgan Healthcare Conference Transcript

Jan 16, 2020 / 05:30PM GMT

Release Date Price: €4.38

Transcript

Eric William Joseph

JP Morgan Chase & Co, Research Division - VP & Senior Analyst

Great. Good morning. I'm Eric Joseph, senior biotech analyst at JPMorgan. Our next presenting company is ZIOPHARM Oncology. And to talk to us a little bit about the company is CEO, Larry Cooper -- sorry, Laurence Cooper. My mistake. The breakout session with the Q&A will be in the Yorkshire room. With that, Laurence.

Laurence James Neil Cooper

ZIOPHARM Oncology, Inc. - CEO & Director

Thanks very much, Eric, and greetings from San Francisco. Forward-looking statements and additional information on our website.

Ziopharm is an independent, and we stress independent, immuno-oncology company focused on developing individualized and cost-effective therapies primarily aimed at the large and unmet needs in solid tumors. The key words on there are independent and that we are focused on solid tumors as we move forward, and I'll get into the technical reasons and the programmatic reasons of why we're so bullish on our company.

We have technologies that

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.